Basilea Pharmaceutica (OTCMKTS:BPMUF) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Tuesday. The brokerage presently has a $51.00 price objective on the stock. Zacks Investment Research‘s price objective points to a potential upside of 12.89% from the stock’s previous close.
According to Zacks, “Basilea Pharmaceutica Ltd. is a commercial stage biopharmaceutical company developing products that address the medical challenge of increasing resistance and non-response to current treatment options in the therapeutic areas of bacterial infections, fungal infections and cancer. With two commercialized drugs, the company is committed to discovering, developing and commercializing innovative pharmaceutical products to meet the medical needs of patients with serious and life-threatening conditions. “
Separately, Cantor Fitzgerald initiated coverage on Basilea Pharmaceutica in a research note on Monday, September 10th. They issued an “overweight” rating for the company.
About Basilea Pharmaceutica
Basilea Pharmaceutica AG, together with its subsidiaries, operates as an integrated biopharmaceutical company. The company focuses on the discovery, development, and commercialization of pharmaceutical products in the therapeutic areas of bacterial and fungal infections, and oncology. It offers isavuconazole, an intravenous and oral antifungal drug for the treatment of invasive mold infections under the name of CRESEMBA worldwide.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Basilea Pharmaceutica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Basilea Pharmaceutica and related companies with MarketBeat.com's FREE daily email newsletter.